Merck & Co. Inc. (MRK)

81.71
0.36 0.44
NYSE : Health Technology
Prev Close 81.35
Open 81.54
Day Low/High 80.96 / 81.70
52 Wk Low/High 52.83 / 81.29
Volume 1.91M
Avg Volume 12.14M
Exchange NYSE
Shares Outstanding 2.58B
Market Cap 210.55B
EPS 2.30
P/E Ratio 34.86
Div & Yield 2.20 (2.44%)
Merck To Hold Third-Quarter 2018 Sales And Earnings Conference Call On October 25

Merck To Hold Third-Quarter 2018 Sales And Earnings Conference Call On October 25

Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2018 sales and earnings conference call with institutional investors and analysts at 8:00 a.

Up To 10-Years Of Follow-up Data Reaffirm Safety Profile Of Investigational Cladribine Tablets

Up To 10-Years Of Follow-up Data Reaffirm Safety Profile Of Investigational Cladribine Tablets

DARMSTADT, Germany, October 10, 2018 /PRNewswire/ -- Real-world evidence and longer clinical trial follow-up show no i ncreased incidence of serious adverse events  Additional post-hoc data analyses support s ustained efficacy of c ladribine t ablets in...

Merck's Broad Oncology Pipeline To Be Highlighted At ESMO 2018 Congress

Merck's Broad Oncology Pipeline To Be Highlighted At ESMO 2018 Congress

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new data from Merck's broad oncology portfolio and robust early pipeline will be presented at the European Society for Medical Oncology (ESMO) 2018 Congress in...

New Efficacy And Safety Data On MS Portfolio To Be Presented At ECTRIMS 2018

New Efficacy And Safety Data On MS Portfolio To Be Presented At ECTRIMS 2018

DARMSTADT, Germany, Oct. 8, 2018 /PRNewswire/ -- Late-breaking Phase II primary endpoint data  for investigational therapy evobrutinib, the first oral BTK inhibitor to show clinical proof-of-concept in RMS Up to 10 years of patient experience provides...

Merck Announces Week 96 Data From Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO™ (doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) For The Treatment Of HIV-1 In Treatment-Naïve Patients

Merck Announces Week 96 Data From Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO™ (doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) For The Treatment Of HIV-1 In Treatment-Naïve Patients

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new results from the Phase 3 DRIVE-AHEAD clinical trial evaluating the efficacy and safety of DELSTRIGO™, a once-daily fixed-dose combination tablet of doravirine (100...

Merck's HIV Therapy DELSTRIGO™ (doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) Meets Primary Efficacy Endpoint In Phase 3 DRIVE-SHIFT Study Evaluating Switch To DELSTRIGO From Other Antiretroviral Treatment Regimens

Merck's HIV Therapy DELSTRIGO™ (doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) Meets Primary Efficacy Endpoint In Phase 3 DRIVE-SHIFT Study Evaluating Switch To DELSTRIGO From Other Antiretroviral Treatment Regimens

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first presentation of data from the Phase 3 DRIVE-SHIFT trial evaluating a switch of medication to DELSTRIGO™, a once-daily fixed-dose combination tablet of...

Merck Announces "Safer Childbirth Cities" Initiative, Issues Call To Action To Reverse The Rise In U.S. Maternal Deaths

Merck Announces "Safer Childbirth Cities" Initiative, Issues Call To Action To Reverse The Rise In U.S. Maternal Deaths

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today a new effort to support cities across the country to help women have a healthy pregnancy and safe childbirth.

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

Biotech and Broadway Come Together to Fight Cancer

Biotech and Broadway Come Together to Fight Cancer

Cancer affects all of us. But the Damon Runyon Cancer Research Foundation has invested $355 million (and counting) in research to fight it. We spent time with its incoming CEO to hear about her journey and how immunotherapies are taking the lead.

The New #13 Most Shorted Dow Component: Merck

The New #13 Most Shorted Dow Component: Merck

The most recent short interest data has been released for the 09/14/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Merck Board Rescinds Mandatory CEO Retirement Policy

Merck Board Rescinds Mandatory CEO Retirement Policy

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that its Board of Directors has rescinded its policy subjecting the company's Chief Executive Officer to mandatory retirement at age 65.

A Bullish Options Play on Allergan

A Bullish Options Play on Allergan

Buyout rumors aside, AGN is a name I still find attractive.

Merck Receives Positive CHMP Opinion For DELSTRIGO™ (doravirine/lamivudine/tenofovir Disoproxil Fumarate) And PIFELTRO™ (doravirine) In The European Union For The Treatment Of HIV-1 Infection

Merck Receives Positive CHMP Opinion For DELSTRIGO™ (doravirine/lamivudine/tenofovir Disoproxil Fumarate) And PIFELTRO™ (doravirine) In The European Union For The Treatment Of HIV-1 Infection

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting of marketing...

Merck and PPL Corp. Still Look Good Here

Both names have enjoyed recent price run-ups and continue to pay decent dividends.

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) In Combination With Pemetrexed And Platinum Chemotherapy For The First-Line Treatment Of Patients With Metastatic Nonsquamous NSCLC, With No EGFR Or ALK Genomic Tumor Aberrations

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) In Combination With Pemetrexed And Platinum Chemotherapy For The First-Line Treatment Of Patients With Metastatic Nonsquamous NSCLC, With No EGFR Or ALK Genomic Tumor Aberrations

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, the company's anti-PD-1 therapy, in combination with pemetrexed (ALIMTA ®) and platinum chemotherapy for the...

Merck To Present At The Morgan Stanley 16th Annual Global Healthcare Conference

Merck To Present At The Morgan Stanley 16th Annual Global Healthcare Conference

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Kenneth C.

Data From Merck's Leading Lung Cancer Research Program With KEYTRUDA® (pembrolizumab) To Be Presented At IASLC 19th World Conference On Lung Cancer

Data From Merck's Leading Lung Cancer Research Program With KEYTRUDA® (pembrolizumab) To Be Presented At IASLC 19th World Conference On Lung Cancer

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that investigational data from the company's leading lung cancer research program with KEYTRUDA, Merck's anti-PD-1 therapy, will be presented at the IASLC 19th World...

FDA Grants Priority Review To Merck's Supplemental Biologics License Application For KEYTRUDA® (pembrolizumab) For The Treatment Of Merkel Cell Carcinoma, A Rare Form Of Skin Cancer

FDA Grants Priority Review To Merck's Supplemental Biologics License Application For KEYTRUDA® (pembrolizumab) For The Treatment Of Merkel Cell Carcinoma, A Rare Form Of Skin Cancer

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Merck & Co Inc is the #10 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Merck & Co Inc also comes in above the median of analyst picks among the broader S&P 500 index components, claiming the #112 spot out of 500.

The New #14 Most Shorted Dow Component: Merck

The New #14 Most Shorted Dow Component: Merck

The most recent short interest data has been released for the 08/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Why Large-Cap Pharma Stocks Like Pfizer and Lilly Might Still Have Upside

Why Large-Cap Pharma Stocks Like Pfizer and Lilly Might Still Have Upside

A 'bullish perfect storm of technical factors' is powering the recent strength in large-cap pharma stocks, says Evercore ISI's Rich Ross.

Here's Why You Should Invest in Immunotherapy Companies

Here's Why You Should Invest in Immunotherapy Companies

Immunotherapy may be the future of fighting cancer and companies are racing to capitalize on that. We spoke with the CEO of the Damon Runyon Cancer Research Foundation to find out why.

Eisai And Merck Announce European Commission Grants Marketing Authorization For LENVIMA® (lenvatinib) As First-Line Treatment In Adults With Advanced Or Unresectable Hepatocellular Carcinoma

Eisai And Merck Announce European Commission Grants Marketing Authorization For LENVIMA® (lenvatinib) As First-Line Treatment In Adults With Advanced Or Unresectable Hepatocellular Carcinoma

Eisai and Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the European Commission (EC) has granted a marketing authorization for the oral receptor tyrosine kinase (RTK) inhibitor LENVIMA ® (lenvatinib), as a...

Drug Companies Start Keeping Prices in Check to Avoid Government Crackdown

Drug Companies Start Keeping Prices in Check to Avoid Government Crackdown

The industry has taken to smaller, voluntary measures to avoid serious federal action on pricing.

Jim Cramer: What Does Politics Have to Do With Johnson & Johnson's P/E?

Jim Cramer: What Does Politics Have to Do With Johnson & Johnson's P/E?

The answer is plenty, but you can't trade that.

Merck Could Suffer a Downward Correction to Unwind the Overbought Conditions

Merck Could Suffer a Downward Correction to Unwind the Overbought Conditions

Merck is vey overbought on a number of time frames.

TheStreet Quant Rating: A+ (Buy)